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Abstract
Paroxysmal dyskinesias/dystonias are rare
movement disorders and can be classified into
paroxysmal kinesigenic dyskinesia (PKD),
paroxysmal non-kinesigenic dyskinesia
(PNKD), and paroxysmal exertion-induced
(PED) dyskinesia. While PKD responds to
anticonvulsants, treatment options for PED
are limited. We report a familial PED case that
responded to methocarbamol and was able to
return to baseline strenuous exercise.

Introduction
Paroxysmal dyskinesias (PDs) are
characterized by episodes of sudden onset
of dystonia, ballism, and choreoathetotic
movements, without loss of consciousness.
The first description of the paroxysmal
movement came from Mount and Reback in
1940. They called it “familial paroxysmal
choreoathetosis.”1 The classification of PDs
was introduced by Lance in 1977 based on
the duration of attacks.2 Demirkiran and
Jankovic in 1995 described the current
classification of PDs based on precipitating
factors.3 They classified them into paroxysmal
kinesigenic dyskinesia (PKD), paroxysmal
non-kinesigenic dyskinesia (PNKD),
and paroxysmal exertion- induced (PED)
dyskinesia.
Lance reported the first case of PED in 1977.2
PED episodes are precipitated by prolonged
exercise or physical exertion. The usual age
of onset for PED is 2 – 30 years. The typical
duration of PED varies from five minutes to
two hours, with a frequency between one per
day to two per month.4 PEDs do not responds
to a specific class of drugs. Some cases may
respond to acetazolamide, antimuscarinics,
and benzodiazepines.4 We are presenting
a case of PED that responded very well to
methocarbamol.

Case
A 23-year-old right-handed man was referred
for the evaluation of exertion-induced
paroxysmal dystonic episodes affecting the
right leg and arm. He began to have these
episodes at the age of 20 with progressive
worsening. He noticed spasms and dystonic
posturing in his right leg after doing his
routine exercises and running. Over the years,
episodes started happening with less exertion.
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He needed to rest for 10 – 20 minutes to
alleviate the symptoms and noticed a latency
of a few hours before the subsequent episode.
His medical history included depression at
the age of 19 that was treated with risperidone
for one year. This caused orolingual tardive
dyskinesia that disappeared one month after
discontinuing the risperidone. His lab work
was normal. Electroencephalograph (EEG),
brain MRI, cervical spine, and thoracic spine
were unremarkable except incidental finding
of small (0.9x0.6 cm) benign pituitary cysts
on brain MRI.
His family history was positive for
paroxysmal exertional dystonia in his father.
His brother and mother were in good health.
His neurological examination was normal at
rest, but he developed mild dystonic eversion
posturing of the right foot during heel
walking.
He was initially managed with
cyclobenzaprine, 10 mg three times per day,
resulting in the reduction of symptoms for
one year. He was next started on carbidopalevodopa 25/100 mg 0.5 tabs three times per
day; however, it produced significant nausea,
dizziness, and dystonic posturing of his
right hand, and therefore was referred to our
Movement Disorders Center. We discontinued
the levodopa and started methocarbamol
750 mg two to three times per day, with
significant improvement in dystonic episodes.
He was able to bike for 5 – 10 miles with
methocarbamol.
We also saw his father, a 50-year-old righthanded man. At age 40, he started to notice
paroxysmal dystonia in his hands after holding
a tight grip for a long time (while hammering
or using tools). Symptoms would begin with
an abnormal sensation of tightness followed
by a spasm in the forearms that would lead
to paroxysmal episodes. At the time, his
episodes were happening once per week and
were lasting for 10 – 15 minutes. Neurological
examination revealed increased latency with
the opening hand after a firm grip. His lab
work was unremarkable. Electromyography
and nerve conduction studies of the upper
extremities were unremarkable as well. He
did not wish to take any medications for his
paroxysmal episodes.

Discussion
In recent years researchers have focused more
on the genetics of paroxysmal dyskinesias.
The most common gene associated with
PED is SLC2A1, which encodes glucose
transporter one (GLU-1) that regulates
glucose transport across the blood-brain
barrier.5 Other significant genetic conditions
linked to PED are pyruvate dehydrogenase
deficiency, GCH1, and ECHS1 mutation.5
The primary PEDs, where the energy
metabolism pathways are involved, may
respond to dietary modifications.5 Although
the knowledge about PED is growing, we do
not yet have a well- established symptomatic
treatment of PED. While our patient decided
against genetic testing, his PED episodes
responded very well to methocarbamol.

Conclusion
In the presented case of PED, the patient had
significant improvement of PED episodes
with methocarbamol, and he was able
to resume his usual physical activity.
Methocarbamol is a centrally acting muscle
relaxant, but its exact mechanism of action
is not clearly understood. We believe that the
role of methocarbamol in PED needs to be
explored further as a potential symptomatic
treatment to help patients regain their daily
living functionality. 
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